Effect of phosphorothioate homo-oligodeoxynucleotides on herpes simplex virus type 2-induced DNA polymerase.
Effects of phosphorothioate oligodeoxynucleotides of different chain length and base composition on herpes simplex virus (HSV) type 2 (strain 333)-induced DNA polymerase have been examined in vitro. The anti-HSV-2 DNA polymerase activity was related to the base composition of the analogs, with the order of potency: deoxycytidine greater than thymidine greater than deoxyadenosine, for compounds with equal chain length. The potency was also related to oligomer chain length, since it was observed that the longer the chain length, the more potent the inhibition exerted. Among all the compounds tested, the phosphorothioate oligodeoxycytidine 28-mer (S-(dC)28) was the most potent inhibitor of HSV-2-induced DNA polymerase. This inhibition was competitive with an activated DNA template with a Ki value of 7 nM. It was also a competitive inhibitor of the DNA polymerase-associated exonuclease activity with a Ki value of 5 nM. In contrast, this compound showed less inhibition of human DNA polymerase alpha, beta, and gamma, as well as HSV-1 (strain KOS) and Epstein-Barr virus-induced DNA polymerase. The possibility that S-oligomers can serve as primers for DNA elongation was also investigated. Poly(dG).S-(dC)28 and poly(dA).S-(T)28 are poor substrates for DNA elongation catalyzed by HSV-2 DNA polymerase. In summary, phosphorothioate oligonucleotides could be anti-template inhibitors of HSV DNA polymerase. This information may lead to the development of a new class of selective anti-HSV agents.
Gao
W Y
WY
Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill 27599-7365.
Stein
C A
CA
Cohen
J S
JS
Dutschman
G E
GE
Cheng
Y C
YC
D000818:Animals; D001667:Binding, Competitive; D002417:Cattle; D004247:DNA / Q000378:metabolism; D003839:Deoxyadenosines / Q000494:pharmacology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D003854:Deoxyribonucleotides / Q000494:pharmacology*; D004790:Enzyme Induction / Q000187:drug effects; D043211:Exodeoxyribonuclease V; D005090:Exodeoxyribonucleases / Q000037:antagonists & inhibitors / Q000378:metabolism; D004854:Herpesvirus 4, Human / Q000201:enzymology; D006801:Humans; D007700:Kinetics; D019384:Nucleic Acid Synthesis Inhibitors; D018139:Simplexvirus / Q000201:enzymology*; D013698:Templates, Genetic; D013873:Thionucleotides / Q000494:pharmacology*; D013936:Thymidine / Q000031:analogs & derivatives / Q000494:pharmacology
D003839:Deoxyadenosines; D003854:Deoxyribonucleotides; D019384:Nucleic Acid Synthesis Inhibitors; D013873:Thionucleotides; D003841:Deoxycytidine; D004247:DNA; D005090:Exodeoxyribonucleases; D043211:Exodeoxyribonuclease V; D013936:Thymidine